Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can corn silk help you lose weight? new trial investigates

NCT ID NCT07378033

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a supplement called Cornfit™, made from corn silk, to see if it helps reduce body fat and manage weight in adults who are overweight or obese. One hundred participants will take either Cornfit™ or a placebo for 12 weeks. Researchers will measure changes in body fat using a special scan (DEXA).

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
corn silk extract (Cornfit™)
What this could lead to
If it works, this could offer a natural supplement option for weight management and body fat reduction.
What could go wrong
This is an early-stage trial with only 100 people, so results may not apply to everyone. The supplement might not work better than a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult males and non-pregnant females aged 19 to 65 years 2. Individuals with a BMI of 25-32kg/m2 who are not taking any obesity related medicines. 3. Able to comply with all required study procedures and schedule. 4. Able to comply and willing to follow the prescribed diet plan. 5. Willing and able to give written informed consent. Exclusion Criteria: 1. Individuals who experienced a weight change of 5% or more within 3 months prior to the screening. 2. Individuals who have taken or used medications, herbal remedies, or health supplements (including probiotics) for anti- obesity purposes (e.g., energy metabolism, appetite suppression, weight control, fat breakdown, carbohydrate blocking, inhibition of fat absorption, or gastrointestinal activity regulation) within 6 months prior to the screening. 3. Individuals who have participated in or experienced a weight-loss program within 3 months prior to the screening. 4. Individuals with Gastrointestinal disease like Crohn's Disease, Inflammatory Bowel Syndrome, Gastric resection, Chronic Inflammation (Kidney, Liver, Pancreas), infectious diseases, Autoimmune diseases, Malabsorption syndrome, Porphyria, Hepatitis B or C carriers. 5. Individuals currently using immunosuppressants; proton pump inhibitors (PPIs), H2 receptor blockers, or nonsteroidal anti-inflammatory drugs (NSAIDs); insulin; thyroid hormone replacement therapy. 6. Individuals who have taken Appetite suppressants, Semaglutide, OTC weight loss supplements 3 to 6 months before the trial. 7. Individuals who have consistently consumed dietary supplements (including protein supplements), teas, beverages, or jellies for weight control or fat reduction purposes. 8. Individuals who have undergone any obesity surgery or any surgery within the last 6 months. 9. Individuals who have consistently taken medications or health supplements for cholesterol improvement or blood circulation enhancement within 6 months prior to the screening. 10. Individuals who have clinically significant diseases or disorders related to the liver, kidneys, pancreas, biliary system, cardiovascular system, respiratory system, endocrine system (e.g., diabetes, thyroid disorders), or central nervous system, or who have malignant tumors as identified in physical or clinical examinations (except those who have not experienced recurrence for over 5 years post-surgery). 11. Individuals with uncontrolled hypertension (systolic blood pressure greater or equal to 160 mmHg or diastolic blood pressure greater or equal to 100 mmHg). 12. Individuals diagnosed with diabetes and taking medications to control blood sugar. 13. Individuals undergoing psychiatric medication or psychotherapy for eating disorders or other mental disorders. 14. Individuals with a history of clinically significant hypersensitivity reactions or those who may exhibit hypersensitivity to the ingredients or similar components of the investigational product. 15. Individuals who have consistently used functional products for cellulite removal or fat breakdown. 16. Heavy smokers (greater or equal to 20 cigarettes/day). 17. Individuals who excessively consume alcohol (greater or equal to 40 g/day for men or greater or equal to20 g/day for women). 18. Individuals whose diagnostic or medical test results at the screening visit show the following AST, ALT, or gamma GTP levels exceeding three times the upper limit of the laboratory reference range. eGFR less 60 mL/min/1.73 m square. 19. Individuals who have participated in other clinical trials or human application studies within 3 months prior to the screening. 20. Pregnant or lactating women or within 6 months of giving birth 21. Individuals deemed unsuitable for participation in the study by the principal investigator based on diagnostic laboratory results or other reasons

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity / overweight are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Raksha health care

    Bangalore, Karnataka, 560119, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.